| abstract |
Ligand drug conjugates having a DRS binding moiety linked via a linker and/or a spacer to a therapeutic agent effective in treating various cancers are provided. In certain embodiments, the ligand-drug conjugation has the following formula: L-(LU-D)p, where L is the Ligand unit, LU is the Linker unit and D is the Drug unit (or cytotoxic agent). The subscript p is an integer from 1 to 20. Thus, a Ligand Drug Conjugate comprises a Ligand unit covalently linked to at least one Drug unit. The Drug unit can be covalently linked directly or via a Linker unit (-LU-). The Ligand unit is a DR5 binding agent, such as an anti-DRS antibody. |